CME Group (CME) Stock Forecast & Price Target

$229.04 +2.48 (+1.09%)

(As of 11/22/2024 ET)

CME Group - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Hold

Based on 15 Analyst Ratings

Sell
4

Hold
7

Buy
4

Based on 15 Wall Street analysts who have issued ratings for CME Group in the last 12 months, the stock has a consensus rating of "Hold." Out of the 15 analysts, 4 have given a sell rating, 7 have given a hold rating, and 4 have given a buy rating for CME.

Consensus Price Target

$224.47
-2.00% Downside

According to the 15 analysts' twelve-month price targets for CME Group, the average price target is $224.47. The highest price target for CME is $258.00, while the lowest price target for CME is $180.00. The average price target represents a forecasted downside of -2.00% from the current price of $229.04.

Get the Latest News and Ratings for CME and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for CME Group and its competitors.

CME Analyst Ratings Over Time

Type	Current Forecast 11/24/23 to 11/23/24	1 Month Ago 10/25/23 to 10/24/24	3 Months Ago 8/26/23 to 8/25/24	1 Year Ago 11/24/22 to 11/24/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	4 Buy rating(s)	4 Buy rating(s)	3 Buy rating(s)	6 Buy rating(s)
Hold	7 Hold rating(s)	7 Hold rating(s)	5 Hold rating(s)	3 Hold rating(s)
Sell	4 Sell rating(s)	4 Sell rating(s)	3 Sell rating(s)	1 Sell rating(s)
Consensus Price Target	$224.47	$222.07	$213.27	$220.00
Forecasted Upside	-2.00% Downside	-3.32% Downside	3.01% Upside	1.29% Upside
Consensus Rating	Hold	Hold	Hold	Moderate Buy

Bill Gates’s Next Big AI Bet: Stargate (Ad)

In February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of my favorite stocks. Shares have jumped by more than 20,000% since then.

I believe we are about to do it again with this new AI project called Stargate

CME Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

CME Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

CME Group Stock vs. The Competition

Type	CME Group	Finance Companies	S&P 500
Consensus Rating Score	2.00	2.49	2.50
Consensus Rating	Hold	Hold	Moderate Buy
Predicted Upside	-2.00% Downside	10.25% Upside	7.66% Upside
News Sentiment Rating	Positive News See Recent CME News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
11/11/2024	Deutsche Bank Aktiengesellschaft 3 of 5 stars		Lower Target	Hold ➝ Hold	$227.00 ➝ $226.00	-0.14%
10/28/2024	Piper Sandler 2 of 5 stars		Boost Target	Overweight ➝ Overweight	$240.00 ➝ $250.00	+10.55%
10/24/2024	Oppenheimer 3 of 5 stars		Boost Target	Outperform ➝ Outperform	$245.00 ➝ $258.00	+12.64%
10/24/2024	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	A. Sabadra Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sector Perform ➝ Sector Perform	$235.00 ➝ $235.00	+2.60%
10/24/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$250.00 ➝ $255.00	+12.12%
10/24/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Equal Weight ➝ Equal Weight	$219.00 ➝ $231.00	+1.70%
Get the Latest News and Ratings for CME and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for CME Group and its competitors with MarketBeat's FREE daily newsletter.
10/17/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Equal Weight ➝ Equal Weight	$210.00 ➝ $233.00	+2.02%
10/8/2024	Redburn Atlantic Subscribe to MarketBeat All Access for the recommendation accuracy rating	S. Clinch Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$244.00	+10.04%
10/3/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Sell ➝ Sell	$195.00 ➝ $198.00	-11.89%
10/3/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Underperform ➝ Underperform	$177.00 ➝ $180.00	-19.49%
9/26/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	W. Katz Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Hold	$221.00	+1.60%
7/25/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Underweight ➝ Underweight	$187.00 ➝ $191.00	-3.65%
7/25/2024	Keefe, Bruyette & Woods Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Market Perform ➝ Market Perform	$212.00 ➝ $213.00	+7.98%
4/25/2024	Rosenblatt Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Sell ➝ Sell	$185.00 ➝ $187.00	-12.04%
3/6/2024	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$225.00 ➝ $245.00	+12.27%
2/7/2023	Credit Suisse Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform	$192.00 ➝ $198.00	+13.30%
1/5/2023	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$226.00 ➝ $220.00	+29.35%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 04:46 AM ET.

Should I Buy CME Group Stock? CME Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Thursday, October 31, 2024. Please send any questions or comments about these CME Group pros and cons to contact@marketbeat.com.

CME Group
Bull Case

Here are some ways that investors could benefit from investing in CME Group Inc.:

CME Group Inc. has a strong financial performance with a consistent increase in revenue and earnings per share over recent quarters, indicating a stable and profitable business.
Analysts have raised the price target for CME Group Inc., suggesting positive growth potential and confidence in the company's future performance.
The company pays a quarterly dividend with a dividend yield of 2.11%, providing investors with a steady income stream.
CME Group Inc. has a low debt-to-equity ratio of 0.10, indicating a healthy financial structure and lower financial risk.
The stock price of CME Group Inc. has shown resilience and stability, trading within a reasonable range, which can be attractive to risk-averse investors.

CME Group
Bear Case

Investors should be bearish about investing in CME Group Inc. for these reasons:

Several analysts have issued sell ratings on CME Group Inc., indicating concerns about the company's future performance or market conditions.
Despite some price target increases, there are also underperform ratings on the stock, suggesting potential challenges or weaknesses in the company's operations.
The stock has a beta of 0.55, indicating lower volatility compared to the market, which may limit potential returns for more aggressive investors seeking higher growth opportunities.
There is a consensus rating of "Hold" on CME Group Inc., implying a lack of strong buy signals from analysts, potentially signaling a stagnant stock performance in the near term.
Investors should consider the company's price-to-earnings ratio of 25.28 and price-to-earnings-growth ratio of 8.74 to assess whether the stock is currently overvalued relative to its growth prospects.

CME Forecast - Frequently Asked Questions

: According to the research reports of 15 Wall Street equities research analysts, the average twelve-month stock price forecast for CME Group is $224.47, with a high forecast of $258.00 and a low forecast of $180.00.
: 15 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for CME Group in the last twelve months. There are currently 4 sell ratings, 7 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" CME shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CME, but not buy additional shares or sell existing shares.
: According to analysts, CME Group's stock has a predicted downside of -2.00% based on their 12-month stock forecasts.
: Over the previous 90 days, CME Group's stock had 2 downgrades by analysts.
: CME Group has been rated by research analysts at Bank of America, Barclays, Citigroup, Deutsche Bank Aktiengesellschaft, Morgan Stanley, Oppenheimer, Piper Sandler, Redburn Atlantic, Royal Bank of Canada, TD Cowen, and The Goldman Sachs Group in the past 90 days.
: Analysts like CME Group less than other "finance" companies. The consensus rating score for CME Group is 2.00 while the average consensus rating score for "finance" companies is 2.49. Learn more on how CME compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

War on Elon Escalates… (Ad)

A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.

One company holds a near-total monopoly on it.

This page (NASDAQ:CME) was last updated on 11/23/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CME Group (CME) Stock Forecast & Price Target